ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive impairments that are significant enough to interfere with daily life. A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction may contribute to cognitive decline in AD. In this trial, the aim is to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug. Stockholm, Sweden – November 4, 2025– ScandiBio Therapeutics AB today announced the initiation of a